scholarly journals Utility of the Modified and High-Sensitivity Modified Glasgow Prognostic Scores for Hypopharyngeal Squamous Cell Carcinoma

OTO Open ◽  
2021 ◽  
Vol 5 (4) ◽  
pp. 2473974X2110674
Author(s):  
Hiroyuki Iuchi ◽  
Junichiro Ohori ◽  
Hisahiro Matsuzaki ◽  
Satoshi Kiyama ◽  
Masaru Yamashita
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Disease Free Survival ◽  
High Sensitivity ◽  
Hazard Ratio ◽  
Hypopharyngeal Squamous Cell Carcinoma ◽  
Univariate Analyses

Objective To determine whether the modified Glasgow prognostic score (mGPS) and high-sensitivity mGPS (HS-mGPS) could predict outcomes among patients with hypopharyngeal squamous cell carcinoma (HSCC). Study Design Retrospective cohort study. Setting Affiliated university hospital. Methods We reviewed the records of 115 patients with histologically confirmed HSCC between March 2007 and December 2019. Univariate and multivariable Cox proportional hazard analyses were performed for overall survival (OS) and disease-free survival (DFS). Results The 5-year OS rates were 84.0% for the mGPS0 group, 47.8% for the mGPS1 group, and 17.9% for the mGPS2 group ( P < .0001), while the 5-year OS rates were 86.7% for the HS-mGPS0 group, 69.0% for the HS-mGPS1 group, and 22.2% for the HS-mGPS2 group ( P < .001). The mGPS and HS-mGPS were both associated with OS in the univariate analyses, although only the HS-mGPS was independently associated with OS (hazard ratio, 2.68 [95% CI, 1.19-6.05]; P < .05). The 5-year DFS rates were 75.8% for the mGPS0 group, 53.0% for the mGPS1 group, and 13.8% for the mGPS2 group ( P < .001), while the 5-year DFS rates were 79.8% for the HS-mGPS0 group, 56.8% for the HS-mGPS1 group, and 11.6% for the HS-mGPS2 group ( P < .001). The mGPS and HS-mGPS were both associated with DFS in the univariate analyses, although only the HS-mGPS was independently associated with DFS (hazard ratio, 2.35 [95% CI, 1.03-5.37]; P < .05). Conclusion Our study suggests that the HS-mGPS is useful as prognostic factor in HSCC.

scholarly journals Impacts of Inflammation-Based Prognostic Scores on Survival in Patients With Hypopharyngeal Squamous Cell Carcinoma

OTO Open ◽  
2020 ◽  
Vol 4 (4) ◽  
pp. 2473974X2097813
Author(s):  
Hiroyuki Iuchi ◽  
Takayuki Kyutoku ◽  
Kotoko Ito ◽  
Hayato Matsumoto ◽  
Junichiro Ohori ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Prognostic Score ◽  
Survival Rates ◽  
Glasgow Prognostic Score ◽  
University Hospital ◽  
Prognostic Scores ◽  
Hypopharyngeal Squamous Cell Carcinoma ◽  
Lymphocyte Ratio

Objective To investigate the predictive accuracies of the modified Glasgow Prognostic Score (mGPS), neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) as prognostic factors for patients with hypopharyngeal squamous cell carcinoma (HSCC). Study Design Retrospective study. Setting University hospital. Methods The records of 106 patients who were histologically diagnosed with HSCC between January 2007 and December 2017 were reviewed. mGPS, NLR, and PLR were analyzed; univariate and multivariate analyses were performed to evaluate the prognosis of overall survival (OS). Results The overall 5-year survival rates of patients with mGPS0, mGPS1, and mGPS2 were 82.0%, 41.9%, and 13.5%, respectively. The overall 5-year survival rates of patients with low and high NLRs and with low and high PLRs were 83.8%, 46.2%, 57.0%, and 59.1%, respectively. mGPS ( P < .001) and NLR ( P < .05) were independently associated with OS, whereas PLR was not. For stage IV HSCC, only mGPS was independently associated with OS ( P = .004). Conclusion mGPS is an excellent prognostic factor for patients with HSCC.

Real-world effectiveness of Glasgow prognostic score and tumor biomarkers in predicting post-relapse survival in patients with recurrent cervical cancer after minimally invasive surgery

2020 ◽  
Author(s):  
Junhui Guo ◽  
Yuanyuan Wang ◽  
Xinxin Wang ◽  
Shengli Zhou ◽  
Peimin Liu
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Data ◽  
Squamous Cell ◽  
Real World ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Tumor Biomarkers ◽  
Recurrent Cervical Cancer

Abstract Background Cervical cancer ranks the third most common malignancy of women worldwide, and recurrence of cervical cancer treatment is the major concern. Carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), squamous cell carcinoma antigen (SCCA) and Glasgow Prognostic Score (GPS) were potential prognostic indicator for cervical cancer. However, none of these markers have been evaluated to predict post-relapse survival in recurrent cervical cancer after treatment based on real-world clinical data. Aim To evaluate biomarkers CEA, CA125, SCCA and Glasgow Prognostic Score (GPS) in predicting post-relapse survival in recurrent cervical cancer after treatment based on real-world clinical data. Results Among the 1607 patients, the majority of patients (75.5%) were non-smokers, and the majority of histologic type (68.3%) was squamous cell carcinoma. Except CEA, there were significant difference between different GPS groups in these markers. Areas under the curves (AUC) for GPS, CEA, CA125 and SCCA were 0.632, 0.617, 0.641 and 0.628, respectively. All clinicopathologic characteristics were significantly correlated with CA125. Higher levels of biomarkers and GPS had lower survival and GPS=2 and SCCA was an independent prognostic factor for survival (P=0.008 and P=0.010, respectively). Conclusions In real-world settings, GPS and tumor biomarkers, especially SCCA to independently predict post-recurrence survival in patients with recurrent cervical cancer.

scholarly journals Treatment patterns and survival outcomes in advanced hypopharyngeal squamous cell carcinoma

2020 ◽  
Author(s):  
Yao-Te Tsai ◽  
Wen-Cheng Chen ◽  
Chih-Yen Chien ◽  
Cheng-Ming Hsu ◽  
Yi-Chan Lee ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cox Regression ◽  
Disease Free Survival ◽  
Primary Treatment ◽  
Free Survival ◽  
Hypopharyngeal Squamous Cell Carcinoma ◽  
Primary Surgery ◽  
Kaplan Meier

Abstract Background This study aimed to evaluate the treatment outcomes of the primary surgery (PS) or concurrent chemoradiotherapy (CCRT) as the initial treatment of hypopharyngeal squamous cell carcinoma (HPSCC). Methods A retrospective cohort study of HPSCC patients with stage III-IV HPSCC in four tertiary referral centers consecutively enrolled from 2003 to 2012, total of 213 (32.6%) patients received PS, and 439 (67.4%) patients received CCRT as their primary treatment. Overall survival (OS) and disease-free survival (DFS) were analyzed by Kaplan-Meier method and Cox regression models. Results The 5-year OS and DFS for patients undergoing PS and CCRT were 45.0% vs 33.1% and 36.2% vs 28.9% ( p < 0.001 and 0.003, respectively). In subgroup analysis, PS was associated with better OS in patients with stage IVA of the disease ( p = 0.002), specifically in those with T4 or N2 classification ( p = 0.021 and 0.002, respectively). Multivariate analysis indicated that stages IVA and IVB and CCRT were independent adverse prognostic factors for OS ( p = 0.004, <0.001, and 0.014, respectively). Furthermore, CCRT was also significantly associated with lower OS rates than PS in stage IVA patients more than 65 years of age and with N2 classification ( p = 0.027 and 0.010, respectively). Conclusions In patients with advanced HPSCC, PS was significantly associated with better prognosis and should be considered a favorable primary treatment in patients with stage IVA of the disease, especially if they are over 65 years of age or have T4 and N2 classification.

scholarly journals The Glasgow Prognostic Score. An useful tool to predict survival in patients with advanced esophageal squamous cell carcinoma

2015 ◽  
Vol 30 (8) ◽  
pp. 580-585 ◽  
Author(s):  
Maria Aparecida Coelho de Arruda Henry ◽  
Mauro Masson Lerco ◽  
Walmar Kerche de Oliveira ◽  
Anderson Roberto Guerra ◽  
Maria Aparecida Marchesan Rodrigues
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
The Glasgow Prognostic Score
Sign in / Sign up

Export Citation Format

Share Document